ACTIN Report (research use only)

PATIENT
EXAMPLE-LUNG-02

REPORT DATE
01-Nov-2024

Gender: Male | Birth year: 1965 | WHO: 1

Tumor: Lung - Squamous cell carcinoma | Lesions: Liver, Lung | Stage: III

Summary

Clinical summary

Relevant systemic treatment history	6/2023-6/2024	**Carboplatin+Pemetrexed continued with Pemetrexed maintenance**
	7/2024-8/2024	**Docetaxel**
Relevant other oncological history	**None**	
Previous primary tumor	**None**	
Relevant non-oncological history	1/2020	**Acute myocardial infarction**
	1/2000	**Bipolar disorder**

Recent molecular results

NGS Lung Panel 1.2 (15-Sep-2024)

Biopsy location	**Lung**
Molecular tissue of origin prediction	**Unknown**
Tumor mutational load / burden	**Unknown / TMB low (8)**
Microsatellite (in)stability	**Stable**
HR status	**Proficient**
High driver mutations	**PIK3CA E545K**
Amplified genes	**None**
Deleted genes	**TP53, KEAP1**
Homozygously disrupted genes	**None**
Gene fusions	**None**
Virus detection	**None**
Potentially actionable events with medium/low driver:	**None**

IHC results

PD-L1: Score < 1%

Example trials that are open and potentially eligible (1 cohort from 1 trial)

Trial	Cohort	Molecular	Warnings
METC 05 PICKME3CA	Dose expansion - monotherapy - NSCLC	PIK3CA E545K	History of Acute myocardial infarction

Example trials that are open and potentially eligible but currently have no slots available (1 cohort from 1 trial)

Trial	Cohort	Molecular	Warnings
METC 01 IEMOEN	Dose escalation - monotherapy		None

Trial Matching Summary

Example trials and cohorts that are potentially eligible, but are closed (1)

Trial	Cohort	Molecular	Warnings
METC 01 IEMOEN	Dose expansion - monotherapy		None

Example trials and cohorts that are considered ineligible (5)

Trial	Cohort	Molecular	Ineligibility reasons
METC 05 PICKME3CA	Dose expansion - monotherapy - Other cancer types	PIK3CA E545K	Has tumor belonging to DOID term(s) lung non-small cell carcinoma
METC 02 KAYRAS	Applies to all cohorts below Dose expansion - monotherapy - Colorectum Dose expansion - monotherapy - NSCLC	None	G12D not detected in KRAS No colorectal cancer
METC 03 NO-SEE797ES	Dose escalation - monotherapy		No variants in codon(s) C797 in EGFR
METC 04 TEDR1	Lung cancer C797S cohort		C797S not detected in EGFR

Open cohorts with no slots available are shown in grey.

Example trials and cohorts that are not evaluable or ignored (0)

None

Trial Matching Details

Potentially eligible open trials & cohorts

METC 01

Potentially eligible	**Yes**
Acronym	**IEMOEN**
Title	**Phase I first-in-human study to evaluate safety of IEMOEN, a new PD-L1 inhibitor in advanced solid tumors**

Rule	Reference	Evaluation
E-02	Has hemoglobin below 6 mmol/l	WARN Hemoglobin 8.2 mmol/L exceeds minimum of 6.0 mmol/L, but measurement occurred before 03-Aug-2024
E-03	Has absolute neutrophil count below 1.5 x 10^9/l	UNDETERMINED No measurement found for absolute neutrophil count
I-01	Patients must be ≥18 years old.	PASS Patient is at least 18 years old
I-02	IEMOEN monotherapy is indicated for the treatment of adults with advanced/metastatic solid tumors.	PASS Patient has solid primary tumor Tumor stage III is considered locally advanced Tumor stage III is considered metastatic
I-03	Patient should have exhausted applicable available standard-of-care treatments.	PASS SOC considered exhausted since platinum doublet in treatment history
E-01	Has an active autoimmune disease that requires systemic treatment and poses a risk according to the investigator.	PASS Patient has no other condition belonging to category autoimmune disease

METC 01 - Dose escalation - monotherapy

Cohort ID	**A**
Potentially eligible?	**Yes**
Open for inclusion?	**Yes**
Has slots available?	**No**

METC 01 - Dose expansion - monotherapy

Cohort ID	**B**
Potentially eligible?	**Yes**
Open for inclusion?	**No**
Has slots available?	**No**

METC 05

Potentially eligible	**Yes**
Acronym	**PICKME3CA**
Title	**A phase 1/2 trial of ABC123 +/- platinum doublet in PIK3CA-mutated solid cancer**

Rule	Reference	Evaluation
I-05	Patient can not have a severe cardiac condition.	WARN Patient has history of condition(s) Acute myocardial infarction, which is indicative of coronary artery disease
I-03	ALAT and ASAT should be at most 3*ULN, or at most 5*ULN in case of liver metastases.	UNDETERMINED ASAT and ALAT are not present or cannot be evaluated
I-01	Patient is ≥18 years old.	PASS Patient is at least 18 years old
I-02	Has locally advanced or metastatic cancer.	PASS Tumor stage III is considered locally advanced Tumor stage III is considered metastatic
I-04	Patient has confirmed activating PIK3CA mutation	PASS Activating mutation(s) detected in gene + PIK3CA: PIK3CA E545K

METC 05 - Dose expansion - monotherapy - NSCLC

Cohort ID	**A**
Potentially eligible?	**Yes**
Open for inclusion?	**Yes**
Has slots available?	**Yes**

Rule	Reference	Evaluation
I-03	Has non small cell lung cancer.	PASS Patient has tumor belonging to DOID term(s) lung non-small cell carcinoma

METC 05 - Dose expansion - monotherapy - Other cancer types

Cohort ID	**B**
Potentially eligible?	**No**
Open for inclusion?	**Yes**
Has slots available?	**Yes**

Rule	Reference	Evaluation
I-03	Has solid cancer, other than non small cell lung cancer.	FAIL Patient has tumor belonging to DOID term(s) lung non-small cell carcinoma

Other trials & cohorts

METC 02

Potentially eligible	No
Acronym	**KAYRAS**
Title	**A phase 1/2 trial for first in-human usage of KAYRAS, a new specific KRAS G12D inhibitor in NSCLC and colorectal cancer**

Rule	Reference	Evaluation
I-04	Patient has confirmed KRAS G12D mutation	FAIL None of G12D detected in gene KRAS

METC 02 - Dose expansion - monotherapy - NSCLC

Cohort ID	**A**
Potentially eligible?	No
Open for inclusion?	**Yes**
Has slots available?	**Yes**

METC 02 - Dose expansion - monotherapy - Colorectum

Cohort ID	**B**
Potentially eligible?	No
Open for inclusion?	**Yes**
Has slots available?	**Yes**

Rule	Reference	Evaluation
I-02	KAYRAS monotherapy is indicated for the treatment of NSCLC or colorectal patients with metastatic cancer.	FAIL Patient has no colorectal cancer

METC 03

Potentially eligible	No
Acronym	**NO-SEE797ES**
Title	**Phase I trial for development of NO-SEE797ES, a specific inhibitor for EGFR with C797 mutations but not C797S in solid tumors**

Rule	Reference	Evaluation
I-03	Tumors should contain EGFR C797 but not EGFR C797S mutation.	FAIL No variants in codon(s) C797 detected in gene EGFR

METC 03 - Dose escalation - monotherapy

Cohort ID	**A**
Potentially eligible?	No
Open for inclusion?	**Yes**
Has slots available?	**Yes**

METC 04

Potentially eligible	No
Acronym	**TEDR1**
Title	**TEDR1 Trial: A phase II trial to evaluate efficacy of specific EGFR inhibitors in lung cancer**

Rule	Reference	Evaluation
I-3	Patient has a confirmed EGFR C797S mutation	FAIL None of C797S detected in gene EGFR

METC 04 - Lung cancer C797S cohort

Cohort ID	**A**
Potentially eligible?	No
Open for inclusion?	**Yes**
Has slots available?	**Yes**